According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
AstraZeneca, Sinopharm and Moderna were part of the study
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Dr. Reddy's has the rights to distribute 250mn doses in India
Subscribe To Our Newsletter & Stay Updated
